Browse > Article
http://dx.doi.org/10.5483/BMBRep.2014.47.7.168

Inhibition of mouse SP2/0 myeloma cell growth by the B7-H4 protein vaccine  

Mu, Nan (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Liu, Nannan (Experiment Teaching Center of Basic Medicine, The Fourth Military Medical University)
Hao, Qiang (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Xu, Yujin (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Li, Jialin (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Li, Weina (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Wu, Shouzhen (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Zhang, Cun (State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy)
Su, Haichuan (Department of Oncology, Tangdu Hospital, Fourth Military Medical University)
Publication Information
BMB Reports / v.47, no.7, 2014 , pp. 399-404 More about this Journal
Abstract
B7-H4 is a member of B7 family of co-inhibitory molecules and B7-H4 protein is found to be overexpressed in many human cancers and which is usually associated with poor survival. In this study, we developed a therapeutic vaccine made from a fusion protein composed of a tetanus toxoid (TT) T-helper cell epitope and human B7-H4IgV domain (TT-rhB7-H4IgV). We investigated the anti-tumor effect of the TT-rhB7-H4IgV vaccine in BALB/c mice and SP2/0 myeloma growth was significantly suppressed in mice. The TT-rhB7-H4IgV vaccine induced high-titer specific antibodies in mice. Further, the antibodies induced by TT-rhB7-H4IgV vaccine were capable of depleting SP2/0 cells through complement-dependent cytotoxicity (CDC) in vitro. On the other hand, the poor cellular immune response was irrelevant to the therapeutic efficacy. These results indicate that the recombinant TT-rhB7-H4IgV vaccine might be a useful candidate of immunotherapy for the treatment of some tumors associated with abnormal expression of B7-H4.
Keywords
B7-H4; Tumor Escape; T-helper Epitope; Tetanus Toxoid; Tumor Vaccine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Salceda, S., Tang, T., Kmet, M., Munteanu, A., Ghosh, M., Macina, R., Liu, W., Pilkington, G. and Papkoff, J. (2005) The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306, 128-141.   DOI   ScienceOn
2 Prasad, D. V., Richards, S., Mai, X. M. and Dong, C. (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18, 863-873.   DOI   ScienceOn
3 Sica, G. L., Choi, I. H., Zhu, G., Tamada, K., Wang, S. D., Tamura, H., Chapoval, A. I., Flies, D. B., Bajorath, J. and Chen, L. (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849-861.   DOI   ScienceOn
4 Krambeck, A. E., Thompson, R. H., Dong, H., Lohse, C. M., Park, E. S., Kuntz, S. M., Leibovich, B. C., Blute, M. L., Cheville, J. C. and Kwon, E. D. (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. U.S.A. 103, 10391-10396.   DOI   ScienceOn
5 Fauci, J. M., Straughn, J. M., Jr., Ferrone, S. and Buchsbaum, D. J. (2012) A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol. Oncol. 127, 420-425.   DOI   ScienceOn
6 Simon, I., Katsaros, D., Rigault de la Longrais, I., Massobrio, M., Scorilas, A., Kim, N. W., Sarno, M. J., Wolfert, R. L. and Diamandis, E. P. (2007) B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol. Oncol. 106, 334-341.   DOI   ScienceOn
7 Dalum, I., Butler, D. M., Jensen, M. R., Hindersson, P., Steinaa, L., Waterston, A. M., Grell, S. N., Feldmann, M., Elsner, H. I. and Mouritsen, S. (1999) Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol. 17, 666-669.   DOI   ScienceOn
8 Chen, L. J., Sun, J., Wu, H. Y., Zhou, S. M., Tan, Y., Tan, M., Shan, B. E., Lu, B. F. and Zhang, X. G. (2011) B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 60, 1047-1055.   DOI
9 Sun, S. Q., Jiang, C. G., Lin, Y., Jin, Y. L. and Huang, P. L. (2012) Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines. J. Int. Med. Res. 40, 497-506.   DOI
10 Dalum, I., Jensen, M. R., Gregorius, K., Thomasen, C. M., Elsner, H. I. and Mouritsen, S. (1997) Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol. 34, 1113-1120.   DOI   ScienceOn
11 Valmori, D., Pessi, A., Bianchi, E. and Corradin, G. (1992) Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149, 717-721.
12 Hansen, J. D., Du Pasquier, L., Lefranc, M. P., Lopez, V., Benmansour, A. and Boudinot, P. (2009) The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol. Immunol. 46, 457-472.   DOI   ScienceOn
13 Yu, Z., Healy, F., Valmori, D., Escobar, P., Corradin, G. and Mach, J. P. (1994) Peptide-antibody conjugates for tumour therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to an anti-Ig light chain antibody can induce cytotoxic lysis of a human B-cell lymphoma by specific CD4 T cells. Int. J. Cancer 56, 244-248.   DOI   ScienceOn
14 Zhang, C., Wang, W., Qin, X., Xu, Y., Huang, T., Hao, Q., Li, W., Wu, S. and Zhang, Y. (2013) B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. Oncol. Rep. 30, 2442-2448.   DOI
15 Suh, W. K., Wang, S., Duncan, G. S., Miyazaki, Y., Cates, E., Walker, T., Gajewska, B. U., Deenick, E., Dawicki, W., Okada, H., Wakeham, A., Itie, A., Watts, T. H., Ohashi, P. S., Jordana, M., Yoshida, H. and Mak, T. W. (2006) Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol. Cell Biol. 26, 6403-6411.   DOI   ScienceOn
16 Zhang, C., Wu, S., Xue, X., Li, M., Qin, X., Li, W., Han, W. and Zhang, Y. (2008) Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV. Cytotherapy 10, 711-719.   DOI   ScienceOn
17 Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., Chen, L., Coukos, G. and Zou, W. (2007) Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67, 8900-8905.   DOI   ScienceOn
18 Choi, I. H., Zhu, G., Sica, G. L., Strome, S. E., Cheville, J. C., Lau, J. S., Zhu, Y., Flies, D. B., Tamada, K. and Chen, L. (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171, 4650-4654.   DOI
19 Renard, V., Sonderbye, L., Ebbehoj, K., Rasmussen, P. B., Gregorius, K., Gottschalk, T., Mouritsen, S., Gautam, A. and Leach, D. R. (2003) HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J. Immunol. 171, 1588-1595.   DOI
20 Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., Lackner, A., Alvarez, X., Ochoa, A., Chen, L. and Zou, W. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881.   DOI   ScienceOn
21 Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. and Seliger, B. (2011) B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 17, 3100-3111.   DOI
22 Lin, C. C., Chou, C. W., Shiau, A. L., Tu, C. F., Ko, T. M., Chen, Y. L., Yang, B. C., Tao, M. H. and Lai, M. D. (2004) Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol. Ther. 10, 290-301.   DOI   ScienceOn